Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
36.26
+0.92 (2.60%)
Dec 20, 2024, 4:00 PM EST - Market closed
Biohaven Employees
Biohaven had 239 employees as of December 31, 2023. The number of employees increased by 37 or 18.32% compared to the previous year.
Employees
239
Change (1Y)
37
Growth (1Y)
18.32%
Revenue / Employee
n/a
Profits / Employee
-$3,365,418
Market Cap
3.67B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Acadia Healthcare Company | 23,500 |
| DENTSPLY SIRONA | 15,000 |
| Organon & Co. | 10,000 |
| Perrigo Company | 9,140 |
| Haemonetics | 3,657 |
| Sotera Health Company | 3,000 |
| Oscar Health | 2,400 |
| PTC Therapeutics | 1,055 |
BHVN News
- 4 days ago - Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - Benzinga
- 5 days ago - Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PRNewsWire
- 15 days ago - Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting - PRNewsWire
- 22 days ago - Biohaven's Revenue Path: SCA And Obesity Therapies - Seeking Alpha
- 26 days ago - Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 26 days ago - Biohaven's spinal muscular atrophy drug fails to meet main goal in study - Reuters
- 26 days ago - Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PRNewsWire
- 5 weeks ago - Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - PRNewsWire